- Home
- ATHA vs NEUP Comparison
ATHA vs NEUP Comparison
Compare ATHA & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- NEUP
- Stock Information
- Founded
- ATHA 2011
- NEUP 1996
- Country
- ATHA United States
- NEUP United States
- Employees
- ATHA N/A
- NEUP N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- NEUP
- Sector
- ATHA Health Care
- NEUP
- Exchange
- ATHA Nasdaq
- NEUP Nasdaq
- Market Cap
- ATHA 14.8M
- NEUP 12.7M
- IPO Year
- ATHA 2020
- NEUP N/A
- Fundamental
- Price
- ATHA $0.40
- NEUP $7.18
- Analyst Decision
- ATHA Hold
- NEUP Strong Buy
- Analyst Count
- ATHA 3
- NEUP 1
- Target Price
- ATHA $0.50
- NEUP $21.00
- AVG Volume (30 Days)
- ATHA 133.3K
- NEUP 29.5K
- Earning Date
- ATHA 08-07-2025
- NEUP 08-29-2025
- Dividend Yield
- ATHA N/A
- NEUP N/A
- EPS Growth
- ATHA N/A
- NEUP N/A
- EPS
- ATHA N/A
- NEUP 0.00
- Revenue
- ATHA N/A
- NEUP $15,662,715.00
- Revenue This Year
- ATHA N/A
- NEUP N/A
- Revenue Next Year
- ATHA N/A
- NEUP N/A
- P/E Ratio
- ATHA N/A
- NEUP $4,237.79
- Revenue Growth
- ATHA N/A
- NEUP N/A
- 52 Week Low
- ATHA $0.22
- NEUP $2.90
- 52 Week High
- ATHA $3.51
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- ATHA 53.29
- NEUP 43.15
- Support Level
- ATHA $0.38
- NEUP $6.82
- Resistance Level
- ATHA $0.41
- NEUP $8.81
- Average True Range (ATR)
- ATHA 0.02
- NEUP 0.54
- MACD
- ATHA -0.00
- NEUP -0.12
- Stochastic Oscillator
- ATHA 71.70
- NEUP 18.28
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.